# Tislelizumab Combined With Nab-paclitaxel and Gemcitabine for Recurrent Pancreatic Cancer

> **NCT04902261** · PHASE2 · UNKNOWN · sponsor: **Changhai Hospital** · enrollment: 140 (estimated)

## Conditions studied

- Recurrent Pancreatic Cancer

## Interventions

- **DRUG:** Tislelizumab
- **DRUG:** Nab paclitaxel
- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT04902261
- **Lead sponsor:** Changhai Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-11-20
- **Primary completion:** 2023-11-20
- **Final completion:** 2023-11-20
- **Target enrollment:** 140 (ESTIMATED)
- **Last updated:** 2023-09-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04902261

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04902261, "Tislelizumab Combined With Nab-paclitaxel and Gemcitabine for Recurrent Pancreatic Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04902261. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*